Elevance Health, Inc. (NYSE:ELV – Get Free Report) declared a quarterly dividend on Wednesday, January 22nd, RTT News reports. Investors of record on Monday, March 10th will be paid a dividend of 1.71 per share on Tuesday, March 25th. This represents a $6.84 annualized dividend and a dividend yield of 1.67%. The ex-dividend date is Monday, March 10th. This is a 4.9% increase from Elevance Health’s previous quarterly dividend of $1.63.
Elevance Health has raised its dividend payment by an average of 13.0% annually over the last three years and has increased its dividend every year for the last 14 years. Elevance Health has a dividend payout ratio of 17.5% meaning its dividend is sufficiently covered by earnings. Analysts expect Elevance Health to earn $39.05 per share next year, which means the company should continue to be able to cover its $6.84 annual dividend with an expected future payout ratio of 17.5%.
Elevance Health Stock Up 1.7 %
ELV stock opened at $409.59 on Friday. The stock’s fifty day simple moving average is $390.64 and its two-hundred day simple moving average is $434.88. The company has a current ratio of 1.45, a quick ratio of 1.50 and a debt-to-equity ratio of 0.71. Elevance Health has a 1-year low of $362.21 and a 1-year high of $567.26. The stock has a market cap of $93.12 billion, a P/E ratio of 15.99, a P/E/G ratio of 1.18 and a beta of 0.83.
Insider Activity at Elevance Health
In related news, EVP Charles Morgan Kendrick, Jr. sold 3,504 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $396.30, for a total value of $1,388,635.20. Following the completion of the sale, the executive vice president now owns 10,116 shares in the company, valued at approximately $4,008,970.80. The trade was a 25.73 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.35% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
Several equities analysts have recently commented on the company. Wells Fargo & Company reduced their price objective on Elevance Health from $483.00 to $478.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $485.00 price objective on shares of Elevance Health in a report on Friday, January 24th. Argus restated a “hold” rating and issued a $405.40 target price on shares of Elevance Health in a research note on Wednesday, January 29th. Truist Financial lowered their target price on Elevance Health from $520.00 to $480.00 and set a “buy” rating for the company in a research note on Monday, January 6th. Finally, StockNews.com raised Elevance Health from a “hold” rating to a “buy” rating in a research report on Saturday, March 1st. Three research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $517.03.
Read Our Latest Analysis on ELV
About Elevance Health
Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.
Read More
- Five stocks we like better than Elevance Health
- Growth Stocks: What They Are, Examples and How to Invest
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- 3 Stocks to Buy While Others Stay on the Sidelines
- 3 Best Fintech Stocks for a Portfolio Boost
- MarketBeat Week in Review – 03/03 – 03/07
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.